Thrombospondin 1-mediated suppression of mast cell degranulation is involved in the efficacy of sublingual immunotherapy
Thrombospondin 1-mediated suppression of mast cell degranulation is involved in the efficacy of sublingual immunotherapy
复制标题
血小板反应蛋白 1 介导的肥大细胞脱颗粒抑制与舌下免疫治疗的疗效有关
DOI：
10.1016/j.alit.2019.03.007
复制
发表时间：
2019
影响因子：
6.8
通讯作者：
Hiroi T.
中科院分区：
文献类型：
--
作者：
Kaminuma O;Kitamura N;Gotoh M;Shindo M;Watanabe N;Saeki M;Nishimura T;Mori A;Nemoto S;Tatsumi H;Okubo K;Hiroi T.
自2014年推出以来，1种舌下免疫疗法（SLIT）药物已在日本获批用于治疗过敏性鼻炎。除了高有效率外，SLIT预期具有疗效也是值得注意的。然而，SLIT发挥其药理作用的机制尚未得到充分表征。CD 4 + T细胞是SLIT的候选靶细胞。最近，Ihara等人报道，外周血中变应原反应性ST 2 + CD 45 + CD 4+细胞的减少与SLIT疗效相关。2SLIT诱导日本雪松花粉症（JCP）小鼠模型中CD 103 + Foxp 3 + CD 4 + T细胞上调。3我们认为CD 4 + T细胞上表达的苦味受体和CD 4 + T细胞的凋亡途径是SLIT对JCP疗效的决定因素。4，5另一个过敏原识别系统，IgE/肥大细胞依赖性途径，对SLIT疗效的贡献是有争议的。尽管皮下免疫疗法（SCIT）经常导致变应原特异性IgE下调和IgE阻断抗体诱导，6但这些效应在SLIT中并不总是明显的。我们还观察到，无论疾病严重程度是否降低，72%的患者在SLIT治疗2年后，JCP患者的过敏原特异性血清IgE升高，而不是降低。7高应答组（HR）和无应答组（NR）之间无显著性差异。
After being introduced in 2014, 1 various sublingual immunotherapy (SLIT) drugs have been approved for treatment of allergic rhinitis in Japan. In addition to high efficacy rates, it is remarkable that SLIT is expected to have curative effects. However, the mechanisms by which SLIT exerts their pharmacological effects are not well-characterized. CD4+ T cells are candidate target cells of SLIT. Recently, Ihara et al. reported that a decrease in allergen-reactive ST2+ CD45+ CD4+ cells in peripheral blood was correlated with SLIT efficacy. 2 Upregulation of CD103+ Foxp3+ CD4+ T cells was induced by SLIT in a murine model of Japanese cedar pollinosis (JCP). 3 We proposed that bitter taste receptors expressed on CD4+ T cells and an apoptosis pathway in CD4+ T cells were determinants of SLIT efficacy against JCP. 4, 5Contributions of another allergen recognition system, an IgE/mast cell-dependent pathway, to SLIT efficacy is controversial. Although downregulation of allergen-specific IgE and induction of IgE blocking-antibody often results from subcutaneous immunotherapy (SCIT), 6 these effects are not always obvious in SLIT. We also observed the increment, rather than decrease, of allergen-specific serum IgE in JCP patients, regardless of decrease in disease severity, in 72% patients after SLIT for 2 years. 7 No significant differences were observed between patients divided into high-responder (HR) and non-responder (NR) groups.